Accutane Bowel Lawsuits in New Jersey Mass Tort Top 2400

There are now 2,441 <"">Accutane inflammatory bowel disease (IBD) lawsuits pending in a New Jersey mass tort litigation that began five years ago. Over the fall, more than 800 lawsuits were filed in the Accutane litigation, and it is expected that more cases will be filed in the future.

Approved by the Food & Drug Administration (FDA) in 1982, Accutane has been the subject of controversy for years. It first garnered attention in the late eighties for causing severe birth defects. It has also been known to cause psychiatric problems, and has been linked to hundreds of cases of suicide in the United States. Accutane has also been associated with problems of the liver, kidneys, central nervous system, and pancreas, as well as the cardiovascular, musculoskeletal and auto-immune systems.

In 2009, Roche decided to stop marketing Accutane for economic reasons. In announcing the decision, Roche cited the high cost of product liability suits involving the drug as one of the factors in the decision.

The spike in <"">Accutane claims filed in New Jersey comes on the heels of a court ruling there that found the statute of limitation for such lawsuit should be based on when plaintiffs discovered there could be a connection between the Accutane and their bowel disorder.

Bloomberg News reported in August that Roche has lost all seven Accutane cases that have been considered by juries since 2007, including the last three in a row. Following one 2007 trial in New Jersey state court, Roche was able to successfully overturn a jury’s award of $2.62 million in compensation awarded to a man who developed inflammatory bowel problems. However, that case was retried earlier this year and another New Jersey jury awarded the same man more than $25 million.

In August, the New Jersey Superior Court Appellate Division threw out an award of $10.5 million stemming from a 2008 Accutane trial, and ordered a new case for that trial.

This entry was posted in Accutane, Pharmaceuticals. Bookmark the permalink.

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.